《生命科学》 2023, 35(3): 340-346
活体菌药物产业化
摘 要：
肠道微生物组通常被认为与胃肠道疾病，如传染性腹泻相关。然而，肠道细菌也可以通过调节人体免疫系统、新陈代谢，甚至神经功能来影响身体远端部位的功能。这是一种进化的功能，允许细菌与身体系统相互作用，并调节身体系统。活体菌药物通过多种机制与人类生物系统相互作用。尽管宿主和微生物相互作用通常在肠道中启动，但产生的下游通路变化是多种多样的，影响身体的肠道和肺部，甚至中枢神经系统。过去10 来年基因组学的发展带动人体微生物组学的繁荣，逐步阐明了人体微生物与人体健康、疾病的关系，也促进了微生物组学产业化的进程。活体菌药物提供了一种治疗广泛范围疾病的新方法，如从癌症到哮喘和中枢神经系统疾病。在临床治疗上，活体菌药物产品也逐渐从研究、发现进入到后期临床阶段。
通讯作者：朱永亮 , Email:zhuyongliang@precisiongene.cn
Abstract:
Intestinal microbiota is generally believed to affect gastrointestinal diseases, such as infectious diarrhea. However, intestinal bacteria can also affect diseases in remote parts of the body by regulating the human immune system, metabolism and even nerve function. It is an evolutionary function that allows bacteria to interact with and regulate the body system. Living bacterial drugs interact with human biological systems through a variety of mechanisms. Although host-microorganism interactions are usually initiated in the gut, the resulted downstream pathway changes are diverse, affecting the intestine, lungs, and even the central nervous system. The development of genomics in the past 10 years has led to the prosperity of human microbiology, gradually clarified the relationship between human microorganisms and human health & diseases, and also promoted the industrialization of microbiology. Living bacteria drugs provide a new method to treat a wide range of diseases, from cancer to asthma and central nervous system diseases. In terms of clinical treatment, living bacteria drug products have gradually
moved from research and discovery to later clinical stage.
Communication Author：ZHU Yong-Liang , Email:zhuyongliang@precisiongene.cn
